Citadel Advisors
ABOS icon

Citadel Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Citadel Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,800
Closed -$56.5K – 12861
2025
Q4 		$56.5K Buy
26,800
+15,200
+131% +$30.2K ﹤0.01% 11974
2025
Q3 		$19.8K Sell
11,600
-2,700
-19% -$3.74K ﹤0.01% 12491
2025
Q2 		$16.6K Sell
14,300
-24,800
-63% -$26.7K ﹤0.01% 12141
2025
Q1 		$43K Buy
39,100
+10,500
+37% +$15K ﹤0.01% 12464
2024
Q4 		$49.2K Buy
28,600
+25,700
+886% +$61.9K ﹤0.01% 12405
2024
Q3 		$7.19K Sell
2,900
-1,100
-28% -$2.98K ﹤0.01% 13377
2024
Q2 		$9.68K Buy
4,000
+2,100
+111% +$6.69K ﹤0.01% 13129
2024
Q1 		$7.7K Buy
1,900
+1,400
+280% +$5.28K ﹤0.01% 13600
2023
Q4 		$1.92K Sell
500
-23,900
-98% -$70.9K ﹤0.01% 13762
2023
Q3 		$101K Buy
24,400
+18,700
+328% +$116K ﹤0.01% 10880
2023
Q2 		$27.4K Sell
5,700
-2,700
-32% -$12.9K ﹤0.01% 12448
2023
Q1 		$34.1K Sell
8,400
-44,900
-84% -$234K ﹤0.01% 12608
2022
Q4 		$288K Sell
53,300
-93,300
-64% -$627K ﹤0.01% 9409
2022
Q3 		$1.47M Buy
+146,600
New +$841K ﹤0.01% 6199

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors's ABOS Position: Q1 2026 in Review

Citadel Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q1 2026, closing a stake of 345,283 shares — an estimated $881K sold.

Citadel Advisors first reported a position in ABOS in Q3 2021 and held it in 14 quarters. The position peaked at $845K in Q3 2025. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Citadel Advisors reported no remaining Acumen Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 345,283 Acumen Pharmaceuticals shares in Q1 2026, an estimated $881K.
  • Citadel Advisors first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 14 quarters.
  • Citadel Advisors's Acumen Pharmaceuticals position peaked at $845K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.